Medicinal Chemistry
&
Drug Discovery Consulting

translating Innovative Targets into Commercial Drugs

transMedChem was established 2012 by Dr. Peter Sennhenn, a passionate medicinal chemist, drug hunter and entrepreneur with 30 years of industry experience and expertise in various therapeutic areas and target families.

transMedChem provides drug discovery advisory and operational execution of small molecule optimization programs along the whole R&D pipeline in an accelerated and cost-efficient manner employing state-of-the art software tools and integrated AI.

Our Expertise: Small Molecule Drug Discovery & Medicinal Chemistry

We specialize in translating and advancing novel protein targets and mode-of-actions (MOA) from basic reasearch into clinical drugs, offering guidance along the entire preclinical R&D pipeline

Mission

transMedChem offers taylormade solutions based on flexible business models, specifically designed for academic institutions, startups, and biotech companies to translate and advance innovative targets and ideas into commercial pharmaceutical products complying with industry standards.

Vision

transMedChem strives to sustainably close the innovation gap between basic research and the pharmaceutical industry by translating basic biomedical science into novel medicines.

Network

transMedChem exploits a broad and well-established expert network that can be accessed to master challenges and identify the most efficient, cost- and time-saving approach to advance your discovery program.

CEO Image
Dr. Peter Sennhenn (CEO)